Cord F Staehler
Siemens
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cord F Staehler.
Genomics, Proteomics & Bioinformatics | 2012
Cord F Staehler; Andreas Keller; Petra Leidinger; Christina Backes; Anoop Chandran; Joerg Wischhusen; Benjamin Meder; Eckart Meese
Co-regulation of genes has been extensively analyzed, however, rather limited knowledge is available on co-regulations within the miRNome. We investigated differential co-expression of microRNAs (miRNAs) based on miRNome profiles of whole blood from 540 individuals. These include patients suffering from different cancer and non-cancer diseases, and unaffected controls. Using hierarchical clustering, we found 9 significant clusters of co-expressed miRNAs containing 2–36 individual miRNAs. Through analyzing multiple sequencing alignments in the clusters, we found that co-expression of miRNAs is associated with both sequence similarity and genomic co-localization. We calculated correlations for all 371,953 pairs of miRNAs for all 540 individuals and identified 184 pairs of miRNAs with high correlation values. Out of these 184 pairs of miRNAs, 16 pairs (8.7%) were differentially co-expressed in unaffected controls, cancer patients and patients with non-cancer diseases. By computing correlated and anti-correlated miRNA pairs, we constructed a network with 184 putative co-regulations as edges and 100 miRNAs as nodes. Thereby, we detected specific clusters of miRNAs with high and low correlation values. Our approach represents the most comprehensive co-regulation analysis based on whole miRNome-wide expression profiling. Our findings further decrypt the interactions of miRNAs in normal and human pathological processes.
Clinical Chemistry | 2015
Andreas Kappel; Christina Backes; Yiwei Huang; Sachli Zafari; Petra Leidinger; Benjamin Meder; Herbert Schwarz; Walter Gumbrecht; Eckart Meese; Cord F Staehler; Andreas Keller
BACKGROUND The implementation of new biomarkers into clinical practice is one of the most important areas in medical research. Besides their clinical impact, novel in vitro diagnostic markers promise to have a substantial effect on healthcare costs. Although numerous publications report the discovery of biomarkers, only a fraction of those markers are routinely used. One key challenge is a measurement system that is compatible with clinical workflows. METHODS We designed a new immunoassay for microRNA (miRNA) quantification. The assay combines streptavidin-linked microparticles, a biotinylated catcher oligonucleotide complementary to a single miRNA species, and finally, a monoclonal antibody to DNA/RNA heterohybrids labeled with acridinium ester. Importantly, our assay runs on standard immunoassay analyzers. After a technical validation of the assay, we evaluated the clinical performance on 4 Alzheimer disease miRNAs. RESULTS Our assay has an analytical specificity of 99.4% and is at the same time sensitive (concentrations in the range of 1 pmol/L miRNA can be reliably profiled). Because the novel approach did not require amplification steps, we obtained high reproducibility for up to 40 biological replicates. Importantly, our assay prototype exhibited a time to result of <3 h. With human blood samples, the assay was able to measure 4 miRNAs that can detect Alzheimer disease with a diagnostic accuracy of 82% and showed a Pearson correlation >0.994 with the gold standard qRT-PCR. CONCLUSIONS Our miRNA immunoassay allowed the measurement of miRNA signatures with sufficient analytical sensitivity and high specificity on commonly available laboratory equipment.
Bioinformatics | 2018
Tobias Fehlmann; Christina Backes; Julia Alles; Ulrike Fischer; Martin Hart; Fabian Kern; Hilde Langseth; Trine B. Rounge; Sinan Uğur Umu; Mustafa Kahraman; Thomas Laufer; Jan Haas; Cord F Staehler; Nicole Ludwig; Matthias Hübenthal; Benjamin Meder; Andre Franke; Hans Peter Lenhof; Eckart Meese; Andreas Keller
Motivation: Although the amount of small non‐coding RNA‐sequencing data is continuously increasing, it is still unclear to which extent small RNAs are represented in the human genome. Results: In this study we analyzed 303 billion sequencing reads from nearly 25 000 datasets to answer this question. We determined that 0.8% of the human genome are reliably covered by 874 123 regions with an average length of 31 nt. On the basis of these regions, we found that among the known small non‐coding RNA classes, microRNAs were the most prevalent. In subsequent steps, we characterized variations of miRNAs and performed a staged validation of 11 877 candidate miRNAs. Of these, many were actually expressed and significantly dysregulated in lung cancer. Selected candidates were finally validated by northern blots. Although isolated miRNAs could still be present in the human genome, our presented set likely contains the largest fraction of human miRNAs. Contact: [email protected]‐saarland.de or [email protected]‐saarland.de Supplementary information: Supplementary data are available at Bioinformatics online.
Nature Methods | 2011
Andreas Keller; Petra Leidinger; Andrea Bauer; Abdou ElSharawy; Jan Haas; Christina Backes; Anke Wendschlag; Nathalia Giese; Christine Tjaden; Katja Ott; Jens Werner; Thilo Hackert; Klemens Ruprecht; Hanno Huwer; Junko Huebers; Gunnar Jacobs; Philip Rosenstiel; Henrik Dommisch; Arne S. Schaefer; Joachim Müller-Quernheim; Bernd Wullich; Bastian Keck; Norbert Graf; Joerg Reichrath; Britta Vogel; Almut Nebel; Sven Uwe Jager; Peer F Staehler; Ioannis Amarantos; Valesca Boisguerin
Archive | 1999
Cord F Staehler; Peer F Staehler; Manfred Mueller; Fritz Staehler; Hans Lindner
Archive | 1999
Fritz Staehler; Cord F Staehler; Peer F Staehler; Hans Lindner
Archive | 1999
Manfred Mueller; Peer F Staehler; Cord F Staehler
Archive | 1999
Fritz Staehler; Cord F Staehler; Peer F Staehler; Hans Lindner
Archive | 2000
Cord F Staehler; Ramon Gueimil; Matthias Scheffler; Peer F Staehler; Anke Heidbrede
Archive | 1999
Cord F Staehler; Fritz Staehler; Peer F Staehler; Manfred Mueller